Arena Turns In FDA Application

Xconomy San Diego — 

San Diego-based Arena Pharmaceuticals (NASDAQ: ARNA) said today it has filed its application to the FDA for clearance to start marketing lorcaserin for weight loss. The application includes information on 18 clinical trials that enrolled almost 8,600 patients, including the pivotal trials known as Bloom and Blossom. The company had forecasted previously it would complete the application by the end of 2009.

By posting a comment, you agree to our terms and conditions.

One response to “Arena Turns In FDA Application”

  1. Lorcaserin says:

    I have been reading that Lorcaserin is similar to fenfluramine but has not shown any of the heart value problems that fenfluramine had. It also looks like the lesser of the side effects of some of the newer obesity meds on the horizen. What about doctors prescribing Lorcaserin with Phentermine. Have there been any studies on that?